

Drug	Schedule	Relative Myelosuppressive Potency of Single Dose Compared with Doxorubicin given by Standard Schedule	Approximate Relative Cardiotoxicity	Cardiotoxicity Index Compared With Doxorubicin Given by Standard Schedule ^c	Recommended Maximum Dose ^b (mg/m ²)
Doxorubicin	Rapid Infusion	1	1	1	400
Doxorubicin	Weekly	1	0.7	0.7	550
Doxorubicin	24 hr infusion	1	0.62	0.62	550
Doxorubicin	48 hr infusion	1	0.57	0.57	625
Doxorubicin	96 hr infusion	1	0.5	0.5	800-1000 ^d
Epirubicin	Rapid Infusion	0.67	0.66	0.44	900
Mitoxantrone	Rapid Infusion	5	0.5	2.5	160
Daunorubicin	Rapid Infusion	0.67	0.75 ^e	0.5 ^e	800 ^e
Idarubicin	Rapid Infusion	5	0.53	2.67	150
Pirarubicin	Rapid Infusion	1	0.62	0.62	650 ^e
Doxorubicin + Dexrazoxane	Rapid Infusion	1 ^e	0.5 ^e	0.5 ^e	800-1000 ^e
Doxorubicin 300 mg/m ² + Dexrazoxane	Rapid Infusion	1 ^e	0.73 ^e	0.73 ^e	550 ^e

From Holland et al, Cancer Medicine, 4th ed

^bDose producing clinically significant congestive heart failure in 5% of patients.

^cDerived by dividing 400 mg/m², the recommended maximum dose of rapid infusion doxorubicin, by the recommended maximum dose for the agent in question. This index can be multiplied by the cumulative dose of a drug to give an approximation of the toxicity that would be expected had the resultant dose of doxorubicin been administered. This can be useful when changing from one drug to another.

^dLess toxic by endomyocardial biopsy

^eInadequate data